Oman Technology Reporter
SEE OTHER BRANDS

Hottest science and technology news from Oman

Oman Technology Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Technology Reporter.

Press releases published on July 21, 2025

ESCO Completes Divestiture Of VACCO Industries

ESCO Completes Divestiture Of VACCO Industries

St. Louis, July 21, 2025 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE:ESE) completed the previously announced divestiture of VACCO Industries to RBC Bearings Incorporated (NYSE: RBC), an international manufacturer and marketer of highly engineered …

AIXA Miner Releases Upgraded AI-Driven ETH and XRP Cloud Mining Plans for Daily Passive Income

AIXA Miner Releases Upgraded AI-Driven ETH and XRP Cloud Mining Plans for Daily Passive Income

Denver, Colorado, July 21, 2025 (GLOBE NEWSWIRE) -- AIXA Miner today announced the launch of its enhanced Ethereum (ETH) and Ripple (XRP) cloud mining contracts, offering a stable and intelligent alternative to high-volatility trading. Designed for …

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of new …

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

– Results Reflect Continued Financial Strength and Deleveraging – BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced certain unaudited preliminary financial results …

XRP price rises, CJB Crypto one-day mining contract becomes more popular

XRP price rises, CJB Crypto one-day mining contract becomes more popular

London, UK, July 21, 2025 (GLOBE NEWSWIRE) -- With the rising prices of mainstream cryptocurrencies such as XRP, ETH and BTC, CJB Crypto has attracted more and more users. In order to meet the needs of users to obtain passive income from digital assets …

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease

PITTSBURGH, July 21, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, published results of a proteomics analysis from the …

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced it intends to invest an …

NextGen Digital Announces Treasury Strategy to Incorporate Crypto Assets, Acquires $1.0 Million in Bitcoin

NextGen Digital Announces Treasury Strategy to Incorporate Crypto Assets, Acquires $1.0 Million in Bitcoin

Vancouver, B.C., July 21, 2025 (GLOBE NEWSWIRE) -- NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) a digital asset and fintech platform focused on bridging traditional capital markets with Web3 infrastructure, …

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and …

Ambiq Announces Launch of Initial Public Offering

Ambiq Announces Launch of Initial Public Offering

Ambiq Announces Launch of Initial Public Offering AUSTIN, Texas, July 21, 2025 (GLOBE NEWSWIRE) -- Ambiq Micro, Inc. (“Ambiq”), a technology leader in ultra-low-power semiconductor solutions for edge AI, today announced the commencement of its initial …

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will …

Digi Power X Announces $15 Million Registered Direct Offering of Common Stock

Digi Power X Announces $15 Million Registered Direct Offering of Common Stock

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. The offering was to a single new fundamental institutional …

ImCheck’s Announces EMA Orphan Drug Designation for ICT01  as Treatment for Acute Myeloid Leukemia

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia

ImCheck’s Announces EMA Orphan Drug Designation for ICT01 as Treatment for Acute Myeloid Leukemia Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy approach in AML Marseille, France, July 21, 2025 – ImCheck …

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populations Reflects growing alignment among …

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains

Kraig Biocraft Laboratories Successfully Completes Lab-to-Field Transition for Three New Spider Silk Production Strains

ANN ARBOR, Mich., July 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the successful completion of the first rearing cycles for its three newest …

SchoolAI's Deep Canvas Integration Helps Educators Reach Every Student, Every Day

SchoolAI's Deep Canvas Integration Helps Educators Reach Every Student, Every Day

LEHI, Utah, July 21, 2025 (GLOBE NEWSWIRE) -- At InstructureCon 2025, SchoolAI unveiled a significant enhancement to its integration with Canvas, the most widely adopted Learning Management System in North America. The deeper Canvas integration, rolling …

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated …

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US An innovative single pill combination of three medicines, including two doses that are …

Dataprana Launches New Energy Division to Expand Its Data Infrastructure Portfolio

Dataprana Launches New Energy Division to Expand Its Data Infrastructure Portfolio

AVENTURA, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- Dataprana, Inc. (“Dataprana”) is broadening its services with the launch of Prana Energy, a new division with a sole focus of expanding the company’s infrastructure portfolio through strategic land and …

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Report Second Quarter 2025 Financial Results on August 4

RESEARCH TRIANGLE PARK, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025. BioCryst management will host a …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service